Goldman Sachs Acts as Sole Book Running Manager, Deal Range $41.15-$41.58
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy BTSG?
The deal range was $41.15-$41.58. Goldman Sachs acted as sole book running manager for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTSG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTSG
Wall Street analysts forecast BTSG stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.330
Low
40.00
Averages
43.20
High
50.00
Current: 41.330
Low
40.00
Averages
43.20
High
50.00
About BTSG
BrightSpring Health Services, Inc. provides home and community-based pharmacy and health solutions for populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, it provides integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. With a focus on senior and specialty patients, the Company’s platform provides pharmacy and provider services (both clinical and supportive care in nature) in lower-cost home and community settings largely to medicare, medicaid, and commercially insured populations. It delivers services through two reportable segments: Pharmacy Solutions and Provider Services. It provides pharmacy services when and where demanded and as required by customers and patients in their homes and communities, often in coordination with its provider’s services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BrightSpring Health Services Projects 2026 Growth and EBITDA of $760M-$790M
- Broad Growth Expectations: BrightSpring Health Services executives at the TD Cowen Health Care Conference outlined expectations for broad-based growth in 2026 across pharmacy and provider services, with CFO Jennifer Phipps highlighting that strong service quality will drive volume growth and enhance margins.
- EBITDA Guidance: Phipps indicated that the company's EBITDA is projected to be between $760 million and $790 million, and excluding contributions from acquired assets from Amedisys LLC, core growth is expected to be between 18% and 23%, reflecting strong market performance.
- Pharmacy Business Challenges: While there are growth opportunities in specialty and infusion areas, Phipps warned that the home and community pharmacy business will face year-over-year headwinds due to customer profitability actions and divestitures, which may impact overall performance.
- Capital Allocation and Acquisitions: Phipps emphasized that BrightSpring will continue to pursue small “tuck-in” acquisitions to drive shareholder value and plans to provide a framework for long-term targets and growth opportunities at the upcoming investor day, demonstrating confidence in future developments.
See More
BrightSpring Health Services Stock Analysis
- Strong Price Momentum: BrightSpring Health Services (BTSG) has seen a 4.2% price increase over the past four weeks, indicating growing investor interest and enhancing its attractiveness in the market.
- Long-Term Return Potential: The stock has gained 14.7% over the past 12 weeks, suggesting that it not only performs well in the short term but also possesses the potential for long-term investment, appealing to investors seeking quick returns.
- High Volatility Characteristics: With a beta of 2.31, BTSG's price moves 131% more than the market, providing higher returns during market fluctuations but also carrying increased risk for investors.
- Valuation Advantage: Trading at a price-to-sales ratio of 0.61 means investors pay only 61 cents for every dollar of sales, indicating that BTSG maintains a reasonable valuation while experiencing rapid growth, suggesting further upside potential.
See More
BrightSpring Health Services Announces Pricing of Secondary Offering
- Offering Details: BrightSpring Health Services has priced a secondary offering of 20 million shares at $41.15 per share, with all proceeds going to the selling stockholders, indicating strong market activity and shareholder confidence.
- Management Involvement: The offering includes participation from an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain management members, reflecting management's confidence in the company's future and potentially enhancing investor perception.
- Share Repurchase Plan: The company plans to concurrently repurchase 1,464,807 shares from the underwriter at the same price as the offering, demonstrating recognition of its stock value and confidence in future market performance.
- Underwriter Role: Goldman Sachs is acting as the sole book-running manager for the offering, ensuring smooth capital inflow and providing professional market support to the company throughout the offering process.
See More
BRIGHTSPRING REVEALS PRICING FOR SECONDARY COMMON STOCK OFFERING AND SIMULTANEOUS SHARE BUYBACK
Announcement of Secondary Offering: Brightspring has announced a secondary offering of common stock.
Concurrent Share Repurchase: The company will also engage in a concurrent share repurchase program.
See More
BrightSpring to Offer 20 Million Shares in Secondary Offering
- Secondary Offering Announcement: BrightSpring Health Services has announced a secondary offering of 20 million shares of common stock, with all proceeds going to the selling stockholders, which will provide liquidity support for the company.
- Share Repurchase Authorization: The company has authorized a concurrent repurchase of up to 10% of the shares sold in the offering or up to $60 million, aimed at enhancing shareholder value and stabilizing the stock price.
- Underwriter Arrangement: Goldman Sachs is acting as the sole book-running manager for the offering, ensuring professionalism and efficiency in the issuance process while providing a transparent information channel for investors.
- Risk Factors Advisory: BrightSpring cautions investors about uncertainties in future performance, which may be influenced by various economic and market factors, and encourages monitoring of its risk factor disclosures with the SEC.
See More
BrightSpring Health Services Q4 2025 Earnings Call Highlights
- Strong Financial Performance: BrightSpring reported total revenue of $3.6 billion in Q4 2025, representing a 29% year-over-year increase, with gross profit of $413 million and adjusted EBITDA of $184 million, reflecting a robust growth trajectory in both revenue and profitability.
- Strategic Acquisition Progress: The company completed the acquisition of Amedisys and LHC home health assets in Q4 2025, expected to contribute $30 million to adjusted EBITDA, thereby enhancing its market position in the home health sector.
- Optimistic Future Outlook: Management anticipates total revenue for 2026 to range between $14.45 billion and $15.0 billion, with adjusted EBITDA projected at $760 million to $790 million, indicating strong confidence in future growth, particularly in Pharmacy Solutions and Provider Services.
- Debt Management Plan: The divestiture of the Community Living business is expected to generate approximately $715 million in after-tax cash proceeds, primarily aimed at debt repayment, which will further improve the company's leverage and strengthen its balance sheet.
See More
BrightSpring Health Services Projects 2026 Growth and EBITDA of $760M-$790M
- Broad Growth Expectations: BrightSpring Health Services executives at the TD Cowen Health Care Conference outlined expectations for broad-based growth in 2026 across pharmacy and provider services, with CFO Jennifer Phipps highlighting that strong service quality will drive volume growth and enhance margins.
- EBITDA Guidance: Phipps indicated that the company's EBITDA is projected to be between $760 million and $790 million, and excluding contributions from acquired assets from Amedisys LLC, core growth is expected to be between 18% and 23%, reflecting strong market performance.
- Pharmacy Business Challenges: While there are growth opportunities in specialty and infusion areas, Phipps warned that the home and community pharmacy business will face year-over-year headwinds due to customer profitability actions and divestitures, which may impact overall performance.
- Capital Allocation and Acquisitions: Phipps emphasized that BrightSpring will continue to pursue small “tuck-in” acquisitions to drive shareholder value and plans to provide a framework for long-term targets and growth opportunities at the upcoming investor day, demonstrating confidence in future developments.
See More
BrightSpring Health Services Stock Analysis
- Strong Price Momentum: BrightSpring Health Services (BTSG) has seen a 4.2% price increase over the past four weeks, indicating growing investor interest and enhancing its attractiveness in the market.
- Long-Term Return Potential: The stock has gained 14.7% over the past 12 weeks, suggesting that it not only performs well in the short term but also possesses the potential for long-term investment, appealing to investors seeking quick returns.
- High Volatility Characteristics: With a beta of 2.31, BTSG's price moves 131% more than the market, providing higher returns during market fluctuations but also carrying increased risk for investors.
- Valuation Advantage: Trading at a price-to-sales ratio of 0.61 means investors pay only 61 cents for every dollar of sales, indicating that BTSG maintains a reasonable valuation while experiencing rapid growth, suggesting further upside potential.
See More
BrightSpring Health Services Announces Pricing of Secondary Offering
- Offering Details: BrightSpring Health Services has priced a secondary offering of 20 million shares at $41.15 per share, with all proceeds going to the selling stockholders, indicating strong market activity and shareholder confidence.
- Management Involvement: The offering includes participation from an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain management members, reflecting management's confidence in the company's future and potentially enhancing investor perception.
- Share Repurchase Plan: The company plans to concurrently repurchase 1,464,807 shares from the underwriter at the same price as the offering, demonstrating recognition of its stock value and confidence in future market performance.
- Underwriter Role: Goldman Sachs is acting as the sole book-running manager for the offering, ensuring smooth capital inflow and providing professional market support to the company throughout the offering process.
See More
BRIGHTSPRING REVEALS PRICING FOR SECONDARY COMMON STOCK OFFERING AND SIMULTANEOUS SHARE BUYBACK
Announcement of Secondary Offering: Brightspring has announced a secondary offering of common stock.
Concurrent Share Repurchase: The company will also engage in a concurrent share repurchase program.
See More
BrightSpring to Offer 20 Million Shares in Secondary Offering
- Secondary Offering Announcement: BrightSpring Health Services has announced a secondary offering of 20 million shares of common stock, with all proceeds going to the selling stockholders, which will provide liquidity support for the company.
- Share Repurchase Authorization: The company has authorized a concurrent repurchase of up to 10% of the shares sold in the offering or up to $60 million, aimed at enhancing shareholder value and stabilizing the stock price.
- Underwriter Arrangement: Goldman Sachs is acting as the sole book-running manager for the offering, ensuring professionalism and efficiency in the issuance process while providing a transparent information channel for investors.
- Risk Factors Advisory: BrightSpring cautions investors about uncertainties in future performance, which may be influenced by various economic and market factors, and encourages monitoring of its risk factor disclosures with the SEC.
See More
BrightSpring Health Services Q4 2025 Earnings Call Highlights
- Strong Financial Performance: BrightSpring reported total revenue of $3.6 billion in Q4 2025, representing a 29% year-over-year increase, with gross profit of $413 million and adjusted EBITDA of $184 million, reflecting a robust growth trajectory in both revenue and profitability.
- Strategic Acquisition Progress: The company completed the acquisition of Amedisys and LHC home health assets in Q4 2025, expected to contribute $30 million to adjusted EBITDA, thereby enhancing its market position in the home health sector.
- Optimistic Future Outlook: Management anticipates total revenue for 2026 to range between $14.45 billion and $15.0 billion, with adjusted EBITDA projected at $760 million to $790 million, indicating strong confidence in future growth, particularly in Pharmacy Solutions and Provider Services.
- Debt Management Plan: The divestiture of the Community Living business is expected to generate approximately $715 million in after-tax cash proceeds, primarily aimed at debt repayment, which will further improve the company's leverage and strengthen its balance sheet.
See More
